TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.